Option Care Health Reports Mixed Q1 Results, Updates 2026 Gross Profit Outlook, and Expands Credit Facility

summarizeSummary

Option Care Health reported mixed Q1 2026 results with slow revenue growth and declining profitability, alongside a new $55 million negative gross profit outlook for 2026. The company significantly increased its revolving credit facility by $450 million, boosting liquidity.

check_boxKey Events

• Mixed Q1 2026 Financial Performance

  Net revenue increased by 1.3% to $1.35 billion, but gross profit decreased by 0.4% to $262.0 million, and operating income fell by 8.4% to $72.5 million compared to Q1 2025. Net income declined by 3.0% to $45.3 million, though diluted EPS slightly increased to $0.29 due to fewer shares outstanding.

• Updated 2026 Gross Profit Outlook

  Management now anticipates a negative impact of approximately $55 million on 2026 gross profit, primarily driven by dynamics within the chronic inflammatory disease (CID) portfolio, including increased patient attrition and unfavorable therapy mix.

• Expanded Revolving Credit Facility

  The company increased its revolving credit commitments by $450 million, bringing the aggregate capacity to $850 million. As of March 31, 2026, $846 million was available for borrowing, significantly enhancing liquidity.

• Reduced Share Repurchase Activity

  Option Care Health repurchased $17.5 million of common stock in Q1 2026, a substantial decrease from $100.0 million in Q1 2025. The company still has $675.0 million remaining under its $1.0 billion share repurchase authorization.

auto_awesomeAnalysis

Option Care Health's first-quarter 2026 results, detailed in this 10-Q, confirm the mixed performance previously indicated by an 8-K filed on the same day. While net revenue saw modest growth, gross profit and operating income declined, and the company experienced increased cash outflow from operations. A significant new detail is management's expectation of a $55 million negative impact on 2026 gross profit due to shifts in the chronic inflammatory disease (CID) portfolio. This operational headwind is a key concern for investors. However, the company substantially bolstered its liquidity by increasing its revolving credit facility by $450 million to an aggregate of $850 million, providing significant financial flexibility. Share repurchase activity slowed considerably compared to the prior year, and the CEO and COO adopted routine 10b5-1 selling plans.